Devonian Reports Human Liver-on-a-Chip Data Demonstrating Disease-Relevant Modulation of MASH by Thykamine(TM), with Dose-Dependent Anti-Fibrotic and Anti-Inflammatory Effects

Executive Summary

• Devonian Health Group reported positive, dose‑dependent anti‑fibrotic and anti‑inflammatory effects of Thykamine™ in a human Liver‑on‑a‑Chip MASH model.
• The highest tested concentrations (0.1 mg/mL and 0.2 mg/mL) produced greater reductions in collagen deposition and pro‑inflammatory cytokines than the reference compound Elafibranor.
• No cytotoxicity was observed, supporting further preclinical development of Thykamine™ for MASH and other fibrotic diseases.

Key Details

• Study Platform: PhysioMimix® Liver‑on‑a‑Chip (CN Bio Innovations, Cambridge, UK) – dynamic triple‑cell model with primary human hepatocytes, Kupffer cells, and hepatic stellate cells under continuous microfluidic flow.
• Dosing Regimen: Thykamine™ tested at 0.025, 0.05, 0.1, and 0.2 mg/mL for 14 days; Elafibranor (20 µM) used as positive control; vehicle control included.
• Fibrosis Biomarkers: Dose‑dependent reductions in pro‑collagen and TIMP‑1 observed; strongest effects at 0.1 mg/mL and 0.2 mg/mL.
• Collagen Deposition: Confocal imaging showed significant decrease in Type I collagen, with higher doses outperforming Elafibranor.
• Inflammatory Cytokines: IL‑6 and IL‑8 levels decreased in a dose‑dependent manner at later time points.
• Cell Health Indicators: LDH remained low throughout; albumin production unchanged, indicating no drug‑induced liver injury.
• CEO Quote: “These findings show that Thykamine™ does more than modulate individual biomarkers—it impacts the core biological processes that define MASH… strengthens the translational rationale for Thykamine™ as a potential disease‑modifying therapeutic candidate.” – Dr. André P. Boulet, CEO.
• Future Plans: Devonian will conduct additional preclinical studies to further characterize Thykamine™’s disease‑modifying potential and support development in MASH and other fibrotic indications.

Notable Quotes

“These findings show that Thykamine™ does more than modulate individual biomarkers—it impacts the core biological processes that define MASH, including fibrosis and inflammation,” – Dr. André P. Boulet, Chairman & CEO.